JP2022553292A5 - - Google Patents
Info
- Publication number
- JP2022553292A5 JP2022553292A5 JP2022523383A JP2022523383A JP2022553292A5 JP 2022553292 A5 JP2022553292 A5 JP 2022553292A5 JP 2022523383 A JP2022523383 A JP 2022523383A JP 2022523383 A JP2022523383 A JP 2022523383A JP 2022553292 A5 JP2022553292 A5 JP 2022553292A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide construct
- binding domain
- receptor
- fragment
- construct according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923644P | 2019-10-21 | 2019-10-21 | |
| US62/923,644 | 2019-10-21 | ||
| PCT/US2020/056723 WO2021081133A1 (en) | 2019-10-21 | 2020-10-21 | Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553292A JP2022553292A (ja) | 2022-12-22 |
| JP2022553292A5 true JP2022553292A5 (enExample) | 2024-01-04 |
Family
ID=75620220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523383A Pending JP2022553292A (ja) | 2019-10-21 | 2020-10-21 | 操作されたナチュラルキラー細胞、ならびに免疫療法およびオートファジー阻害技法においてそれを使用するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220362299A1 (enExample) |
| EP (1) | EP4048292A4 (enExample) |
| JP (1) | JP2022553292A (enExample) |
| AU (1) | AU2020371628A1 (enExample) |
| CA (1) | CA3155246A1 (enExample) |
| WO (1) | WO2021081133A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN113621073A (zh) * | 2021-07-14 | 2021-11-09 | 上海易慕峰生物科技有限公司 | 一种新型嵌合受体组合物、重组载体、细胞及其应用 |
| CN120459135B (zh) * | 2025-07-16 | 2025-10-10 | 深圳市中佳生物医疗科技有限公司 | Cd73+nk细胞在制备预防或治疗帕金森的药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2948544A4 (en) * | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| GB2538120A (en) * | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
| AU2015349878A1 (en) * | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| CN108884459B (zh) * | 2016-04-26 | 2024-04-02 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| US20180100016A1 (en) * | 2016-12-22 | 2018-04-12 | Xiaotong Song | Use of car-modified human natural killer cells to treat cancer |
| CN110650975B (zh) * | 2017-05-15 | 2024-04-05 | 美国卫生和人力服务部 | 双顺反子嵌合抗原受体及其用途 |
-
2020
- 2020-10-21 WO PCT/US2020/056723 patent/WO2021081133A1/en not_active Ceased
- 2020-10-21 EP EP20879537.7A patent/EP4048292A4/en active Pending
- 2020-10-21 AU AU2020371628A patent/AU2020371628A1/en active Pending
- 2020-10-21 CA CA3155246A patent/CA3155246A1/en active Pending
- 2020-10-21 US US17/770,585 patent/US20220362299A1/en active Pending
- 2020-10-21 JP JP2022523383A patent/JP2022553292A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12497456B2 (en) | Bispecific recombinant protein and use thereof | |
| JP7836780B2 (ja) | がんを処置するための改変ｎｋ－９２細胞 | |
| JP2022553292A5 (enExample) | ||
| CN110382539B (zh) | 用于cd16a定向的nk细胞结合的串联双抗体 | |
| CN113227379A (zh) | 多功能多靶向嵌合抗原受体（car）系统及其使用方法 | |
| EP4056596A1 (en) | Bispecific fusion protein and application thereof | |
| US11970545B2 (en) | T cell-antigen coupler with Y182T mutation and methods of uses thereof | |
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| KR20050108349A (ko) | 영속적인 티 세포 반응을 유도하는 삼량체 폴리펩티드 구조물 | |
| CA3042613A1 (en) | Chimeric antigen receptor | |
| JP2023548974A (ja) | Ｔ細胞抗原カプラを含む細胞及びその使用 | |
| WO2021238904A1 (zh) | Fc-CD80融合蛋白和其缀合物以及它们的用途 | |
| WO2024012457A1 (zh) | 三特异性抗体及其用途 | |
| WO2023104214A1 (zh) | 包含lrrc15抗原结合结构域的多特异性t细胞接合剂 | |
| CN115335407B (zh) | 结合cd19的嵌合抗原受体及其用途 | |
| WO2024078479A1 (zh) | 一种异源二聚体融合蛋白及其应用 | |
| CA3062479A1 (en) | Bispecific recombinant protein and use thereof | |
| CN114685675B (zh) | 双特异性抗体及其在治疗癌症中的用途 | |
| CN114075287B (zh) | 人源化bcma抗体和bcma-car-t细胞 | |
| WO2023066322A1 (zh) | 一种融合多肽及其用途 | |
| ZA200508279B (en) | Pharmaceutical composition comprising a bispecific antibody for epcam | |
| CN110339364B (zh) | Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗 | |
| CN112321712B (zh) | 抗Tim3的抗体、嵌合抗原受体及其应用 | |
| TW202607043A (zh) | 多功能融合多肽 | |
| CN121511263A (zh) | 一种多功能融合多肽 |